Praxis Precision Medicines (PRAX) Projected to Post Earnings on Friday

Praxis Precision Medicines (NASDAQ:PRAX) is projected to release its Q1 2026 results before the market opens on Friday, May 1st. Analysts expect Praxis Precision Medicines to post earnings of ($3.66) per share and revenue of $0.10 million for the quarter. Individuals can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 8, 2026 at 9:30 AM ET.

Praxis Precision Medicines (NASDAQ:PRAX) last released its quarterly earnings data on Thursday, February 19th. The company reported ($3.50) earnings per share for the quarter, missing the consensus estimate of ($3.00) by ($0.50). On average, analysts expect Praxis Precision Medicines to post $-15 EPS for the current fiscal year and $-10 EPS for the next fiscal year.

Praxis Precision Medicines Stock Performance

Praxis Precision Medicines stock opened at $329.60 on Friday. The firm has a market cap of $9.18 billion, a PE ratio of -24.49 and a beta of 2.94. The firm’s 50 day moving average price is $317.77 and its two-hundred day moving average price is $260.76. Praxis Precision Medicines has a twelve month low of $34.85 and a twelve month high of $356.00.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Citigroup reiterated a “conviction-buy” rating on shares of Praxis Precision Medicines in a research note on Tuesday, December 30th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Praxis Precision Medicines in a research note on Monday, December 29th. Wolfe Research assumed coverage on shares of Praxis Precision Medicines in a research note on Monday, February 23rd. They issued an “outperform” rating and a $500.00 price objective on the stock. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $437.00 price objective on shares of Praxis Precision Medicines in a research note on Wednesday, April 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $1,245.00 price objective on shares of Praxis Precision Medicines in a research note on Tuesday, April 7th. Five analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $590.78.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Orbis Allan Gray Ltd bought a new stake in shares of Praxis Precision Medicines during the 4th quarter worth $369,946,000. RA Capital Management L.P. bought a new stake in shares of Praxis Precision Medicines during the 4th quarter worth $110,170,000. Woodline Partners LP boosted its holdings in shares of Praxis Precision Medicines by 808.9% during the 3rd quarter. Woodline Partners LP now owns 417,669 shares of the company’s stock worth $22,136,000 after buying an additional 371,717 shares during the period. T. Rowe Price Investment Management Inc. bought a new stake in shares of Praxis Precision Medicines during the 4th quarter worth $81,464,000. Finally, Logos Global Management LP boosted its holdings in shares of Praxis Precision Medicines by 200.0% during the 4th quarter. Logos Global Management LP now owns 375,000 shares of the company’s stock worth $110,528,000 after buying an additional 250,000 shares during the period. Institutional investors and hedge funds own 67.84% of the company’s stock.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.